SPARC and neoplasm: The anti-angiogenic effects of SPARC have been long recognized as evidenced by its inhibitory effect on endothelial cell proliferation and migration in vitro and in vivo by increased angiogenesis and tumor growth in syngeneic tumors implanted in SP−/− mice and paradoxically, decreased angiogenesis and growth of human tumor xenografts expressing SPARC [7, 9, 19, 21–25, 81–83].